Celgene's $4 Billion Bet That Its Stock Is Cheap
Celgene Corp. (NASDAQ: CELG), a biopharmaceutical company focused on creating treatments for cancer and inflammatory diseases, announced this week that it would add $4 billion to its existing share repurchase program. This means the company now has the green light to repurchase $5.2 billion more of its stock on the open market.
Stock buybacks are one method by which companies return cash to their shareholders. When a company repurchases stock it lowers the total amount of shares outstanding, which makes each remaining shareholder own a slightly higher percentage of the company. When performed correctly, stock repurchases are a terrific way for management teams to reward long-term shareholders.
Hey, check out all the research scientist jobs. Post your resume today!
Stock buybacks are one method by which companies return cash to their shareholders. When a company repurchases stock it lowers the total amount of shares outstanding, which makes each remaining shareholder own a slightly higher percentage of the company. When performed correctly, stock repurchases are a terrific way for management teams to reward long-term shareholders.
Hey, check out all the research scientist jobs. Post your resume today!